Earnings summaries and quarterly performance for Immuneering.
Executive leadership at Immuneering.
Benjamin J. Zeskind
Detailed
President and Chief Executive Officer
CEO
BH
Brett Hall
Detailed
Chief Scientific Officer
HE
Harold E. Brakewood
Detailed
Chief Business Officer
IM
Igor Matushansky
Detailed
Chief Medical Officer
LR
Leah R. Neufeld
Detailed
Chief People Officer
MM
Mallory Morales
Detailed
Chief Accounting Officer and Treasurer
MD
Michael D. Bookman
Detailed
Chief Legal Officer and Secretary
Board of directors at Immuneering.
Research analysts who have asked questions during Immuneering earnings calls.
JH
Jeff Hung
Morgan Stanley
1 question for IMRX
Also covers: ACAD, ALEC, BHVN +10 more
MB
Mark Breidenbach
Oppenheimer & Co. Inc.
1 question for IMRX
Also covers: ACAD, AGIO, SYBX
Michael Schmidt
Guggenheim Securities
1 question for IMRX
Also covers: ADAP, ADCT, ARVN +20 more
Michael Yee
Jefferies
1 question for IMRX
Also covers: ABBV, ALLO, AMGN +19 more
SM
Swapnil Malekar
Piper Sandler
1 question for IMRX
YW
Yaron Werber
TD Cowen
1 question for IMRX
Also covers: ALEC, AMGN, ARGX +15 more
Recent press releases and 8-K filings for IMRX.
Immuneering Reports Strong Phase 2a Atebimetinib Pancreatic Cancer Data and Outlines Phase 3 Plans
IMRX
New Projects/Investments
Product Launch
Guidance Update
- Immuneering reported 64% overall survival at 12 months for atebimetinib plus modified gemcitabine nab-paclitaxel in its ongoing Phase 2a study for first-line pancreatic cancer, significantly exceeding the 35% benchmark for standard of care.
- The company is fully funded and has FDA and EMA alignment to commence the pivotal Phase 3 MAPKeeper 301 study for atebimetinib in first-line pancreatic cancer, with the first patient expected to be dosed in mid-2026.
- Atebimetinib, a Deep Cyclic Inhibitor, is designed to improve overall survival through three distinct mechanisms: durable tumor shrinkage, preservation of body mass, and minimization of side effects.
- Immuneering plans to report overall survival data from an expanded cohort of over 50 first-line pancreatic cancer patients in the first half of 2026.
2 days ago
Immuneering provides update on atebimetinib for pancreatic cancer and upcoming milestones
IMRX
New Projects/Investments
- Immuneering reported 64% overall survival at 12 months in its Phase IIa study of atebimetinib plus modified gemcitabine nab-paclitaxel in first-line pancreatic cancer patients, significantly higher than the 35% benchmark for standard of care.
- The company is aligned with FDA and EMA to proceed with a Phase III (MAPKeepeR-301) global randomized pivotal trial for atebimetinib in first-line pancreatic cancer, with the first patient expected to be dosed in mid-2026.
- Immuneering plans to release overall survival data from an expanded cohort of over 50 first-line pancreatic cancer patients in the first half of 2026.
- Atebimetinib, a Deep Cyclic Inhibitor, has a composition of matter patent granted in the U.S., providing exclusivity into at least 2042, potentially 2044 with extensions.
2 days ago
Immuneering discusses atebimetinib's potential in pancreatic cancer and upcoming Phase 3 trial
IMRX
New Projects/Investments
Product Launch
Guidance Update
- Immuneering reported 64% overall survival at 12 months in its Phase 2a study of atebimetinib in first-line pancreatic cancer, significantly exceeding the 35% benchmark for standard of care.
- The company is fully funded and aligned with FDA and EMA to initiate the MAPKeeper 301 Phase 3 study for atebimetinib in first-line pancreatic cancer, with the first patient expected to be dosed in mid-2026.
- Atebimetinib, a Deep Cyclic Inhibitor, is designed to improve overall survival through durable tumor shrinkage, body mass preservation, and minimized side effects.
- Immuneering anticipates reporting overall survival data from an expanded cohort of over 50 patients in the first half of 2026.
2 days ago
Immuneering Reports Positive 12-Month Overall Survival Data for Atebumetanib in Pancreatic Cancer
IMRX
New Projects/Investments
- Immuneering announced 12-month overall survival of 64% for atebumetanib plus chemotherapy in first-line pancreatic cancer patients, significantly higher than the historical benchmark of approximately 35% for standard of care.
- The median overall survival for atebumetanib has not yet been reached at a median follow-up of 13.4 months, compared to approximately 8.5 months for standard of care, and the drug demonstrated a favorable safety and tolerability profile with dramatic improvements in quality of life.
- The company plans to initiate its pivotal Phase 3 clinical trial (MapKeeper 301) for atebumetanib in first-line pancreatic cancer patients in mid-2026, with top-line results anticipated in mid-2028.
- Immuneering maintains a strong financial position with a cash runway extending into 2029, which is expected to fund the company through the pivotal data readout and the initiation of additional trials.
Jan 7, 2026, 9:30 PM
Immuneering Reports Positive 12-Month Overall Survival Data for Atebumetanib in Pancreatic Cancer and Outlines Phase 3 Plans
IMRX
Product Launch
New Projects/Investments
- Immuneering Corporation announced on January 7, 2026, positive 12-month overall survival (OS) data from its phase 2A trial of atebumetanib in first-line pancreatic cancer patients.
- The trial demonstrated a 64% OS rate at 12 months, nearly double the approximately 35% historical benchmark for standard of care, with median OS not yet reached.
- The company plans to initiate a pivotal phase 3 clinical trial (MapKeeper 301) for atebumetanib in first-line pancreatic cancer, with dosing expected to begin in mid-2026 and top-line results anticipated in mid-2028.
- Immuneering maintains a strong financial foundation with a cash runway extending into 2029, supporting key development milestones including the phase 3 data readout.
- An update on overall survival from an expanded cohort of over 50 patients is expected in the first half of 2026, with current trends showing consistency with the initial 34 patients.
Jan 7, 2026, 9:30 PM
Immuneering Reports Positive 12-Month Overall Survival Data for Atebumetanib in Pancreatic Cancer
IMRX
New Projects/Investments
- Immuneering (IMRX) announced positive 12-month overall survival (OS) data from its ongoing Phase 2A trial of atebumetanib in first-line pancreatic cancer patients, achieving 64% OS compared to a historical benchmark of approximately 35% for standard of care.
- The median overall survival for atebumetanib in the study has not yet been reached, with a median follow-up time of 13.4 months.
- The trial also demonstrated significant improvements in secondary endpoints, including a median progression-free survival of 8.5 months (compared to 5.5 months for standard of care) and an overall response rate of 39% (compared to 23%).
- Immuneering plans to initiate a pivotal Phase 3 clinical trial (MapKeeper 301) for atebumetanib in first-line pancreatic cancer, with dosing expected to begin in mid-2026 and top-line results anticipated in mid-2028.
- The company reported a strong financial foundation with a cash runway into 2029, which is expected to fund through the pivotal data readout and initiation of additional trials.
Jan 7, 2026, 9:30 PM
Immuneering Corporation Reports Positive Interim Phase 2a Clinical Trial Data for Atebimetinib
IMRX
New Projects/Investments
- Immuneering Corporation announced updated interim data from its Phase 2a clinical trial for atebimetinib in first-line pancreatic cancer patients, showing 64% overall survival (OS) at 12 months compared to 35% for standard of care, as of a December 15, 2025 cutoff date.
- The trial reported a median progression-free survival (PFS) of 8.5 months, and the median OS had not yet been reached for the initial intent-to-treat population of 34 patients.
- Atebimetinib in combination with mGnP continued to be generally well tolerated, with Grade ≥ 3 treatment-emergent adverse events (TEAEs) observed in 10% or greater of patients consisting of Anemia (18%) and Neutropenia (18%), and no Grade 5 TEAEs or new safety signals identified.
- The company anticipates dosing the first patient in a pivotal Phase 3 clinical trial of atebimetinib in first-line pancreatic cancer in mid-2026, and announcing further updated survival data in the first half of 2026.
Jan 7, 2026, 9:10 PM
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial
IMRX
New Projects/Investments
- Immuneering Corporation (IMRX) will host a conference call and webcast on January 7, 2026, at 4:00 p.m. ET to provide a clinical update.
- The update will include 12-month overall survival (OS) data from its Phase 2a clinical trial of atebimetinib + modified Gemcitabine / nab-paclitaxel (mGnP) in first-line pancreatic cancer patients.
- The company expects to begin dosing a Phase 3 trial for atebimetinib in first-line pancreatic cancer in mid-2026.
Dec 23, 2025, 1:00 PM
Immuneering Reports Strong Pancreatic Cancer Trial Data and Extends Cash Runway
IMRX
Product Launch
New Projects/Investments
Guidance Update
- Immuneering Corporation reported an 86% overall survival at 9 months in first-line pancreatic cancer patients treated with atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP).
- The company raised $225 million in cumulative financing, including a $25 million private placement with Sanofi.
- Immuneering's cash position of $227.6 million as of September 30, 2025, extends its financial runway into 2029, covering the topline readout of its planned Phase 3 trial.
- The company expects to report updated survival data from its atebimetinib + mGnP study in the first half of 2026 and plans to dose the first patient in its pivotal Phase 3 trial by mid-2026.
Dec 12, 2025, 3:47 PM
Immuneering Provides Clinical Update on Etabimetinib for Pancreatic Cancer
IMRX
New Projects/Investments
Guidance Update
- Immuneering reported extraordinary overall survival data and favorable tolerability from its Phase 2A study of Etabimetinib in first-line pancreatic cancer patients, showing 94% overall survival at six months and 86% at nine months as of August 26, 2025.
- These results represent a significant improvement over the standard of care, with a 27-point separation in overall survival at six months and a 39-point separation at nine months compared to typical expectations for gemcitabine-nab-paclitaxel.
- The company plans to initiate a global randomized Phase 3 study for Etabimetinib in first-line pancreatic cancer, with the first patient expected to be dosed in mid-2026.
- Recent financing and strategic investment have provided Immuneering with a financial runway into 2029.
Dec 4, 2025, 4:10 PM
Quarterly earnings call transcripts for Immuneering.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more